Novo Nordisk Offers €2.6bn For Ablynx

Danish diabetes drug specialist Novo Nordisk has offered €2.6bn in cash to acquire Ablynx. The Belgian firm is playing hard to get: this is the second offer from Novo but it is still refusing to talk.

Novo Nordisk AS has revealed that it has made two offers to acquire Ablynx NV, the Belgian antibody fragment specialist with a drug on the verge of approval for the rare blood condition thrombotic thrombocytopenic purpura (aTTP). The first was made on Dec. 6, 2017, and the second, 14% higher at €2.6bn in cash, on Dec. 22. It said the Belgian firm had "declined to engage in any discussions, despite the proposals which have been put forward."

Novo Nordisk said "combining Ablynx's caplacizumab with Novo Nordisk's strong global hematology franchise and extensive worldwide resources is a compelling...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.